Colorectal cancer (CRC) is one of the most common
|
|
- Robyn Reynolds
- 5 years ago
- Views:
Transcription
1 Microsatellite Instability in Colorectal Carcinoma The Comparison of Immunohistochemistry and Molecular Biology Suggests a Role for hmlh6 Immunostaining Valérie Rigau, MD; Nicole Sebbagh, BS; Sylviane Olschwang, MD, PhD; François Paraf, MD, PhD; Najat Mourra, MD; Yann Parc, MD; Jean-François Flejou, MD, PhD Context. Microsatellite instability (MSI) due to defective mismatch repair (MMR) genes has been reported in the majority of colorectal tumors from patients with hereditary nonpolyposis colorectal cancer syndrome and in 1% to 15% of sporadic colorectal cancers. The identification of cancers associated with MSI requires classical molecular testing as the gold standard. Objective. The aim of this study was to evaluate the role of immunohistochemistry with antibodies directed against 4 MMR proteins as a screening tool for carcinomas with MSI. Methods. In this study, 24 formalin-fixed, paraffinembedded colorectal carcinomas were examined for MMR protein expression (, hmsh6, and hpms2) and analyzed for MSI (MSI-H indicates at least 2 of 6 markers affected). These results were correlated with histopathologic parameters. Results. Immunohistochemical analysis revealed that loss of expression of at least 1 protein was present in 17% of cases. One hundred percent of carcinomas that showed high instability (MSI-H) showed loss of expression of, or hmsh6. Loss of expression of 2 proteins was present in 5.4% of MSI-H cases, with only 2 combinations, namely, hmlh1/hpms2 and hmsh2/ hmsh6. Isolated loss of hmsh6 expression was present in 2 MSI-H cases. Conclusions. These findings confirm that examination of MMR protein expression by immunohistochemistry is a simple method to diagnose colorectal cancer with MSI. Our data suggest that the study of hmsh6 may be useful, in addition to hmlh1 and hmsh2. Moreover, immunohistochemistry could represent a screening method with which to direct research on the mutations of MMR genes observed in hereditary nonpolyposis colorectal cancer syndrome. (Arch Pathol Lab Med. ;127:64 7) Colorectal cancer (CRC) is one of the most common forms of cancer in western countries. In most cases, these cancers are seen sporadically, but 5% to 1% of cases are associated with a primary genetic factor. Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common syndrome. It is secondary to an inherited mutation in one of the D mismatch repair (MMR) genes (, hmsh6, and hpms2). 1,2 The phenomenon of microsatellite instability (MSI) results from inactivation, mutational and/or epigenetic, of MMR genes, mostly hmlh1 and hmsh2. 3 It is a characteristic molecular finding in most cases of HNPCC and is also observed in a subgroup (1% 15%) of sporadic CRCs. 4 It has been shown that MSI tumors, either hereditary or sporadic, have particular morphologic features 5 11 Accepted for publication January,. From the Departments of Pathology (Drs Rigau, Mourra, and Flejou, and Ms Sebbagh), Surgery (Drs Olschwang and Parc), AP-HP, Hôpital Saint-Antoine, Paris, France; Centre d Etude du Polymorphisme Humain (CEPH) and Institut National de la Santé et de la Recherche Médicale (INSERM) U434, Paris, France (Drs Rigau, Olschwang, Parc, and Flejou, and Ms Sebbagh); and the Department of Pathology, Hôpital Dupuytren, Limoges, France (Dr Paraf). Reprints: Jean-François Flejou, MD, PhD, Service d Anatomie Pathologique, Hôpital Saint-Antoine, AP-HP 184, rue du Faubourg Saint- Antoine, 75571, Paris cedex 12, France ( jean-francois.flejou@ sat.ap-hop-paris.fr). and, most importantly, have an improved survival rate relative to microsatellite-stable (MSS) tumors of similar stage, 12,13 and may have distinct sensitivity to the action of certain commonly used chemotherapeutic agents. Therefore, it appears that recognition of the microsatellite phenotype is becoming important in the management of patients with CRC. Determination of tumor microsatellite status by polymerase chain reaction has been suggested as the best method to recognize MSI-positive CRC. 15 However, the demonstration by immunohistochemistry of loss of expression of MMR proteins has been proposed as an alternative method to recognize these tumors. 5,,11,16 32 In most studies, only hmlh1 and hmsh2 proteins were studied, although rare cases of HNPCC are secondary to mutations in other MMR genes. Moreover, the expression of other MMR proteins has not been studied extensively in sporadic CRC. The aim of this study was to compare the expression of 4 MMR proteins (, hmsh6, and hpms2) to the MSI status determined by polymerase chain reaction in a series of 24 CRCs. MATERIALS AND METHODS Samples Resection specimens were obtained from 24 patients who underwent surgical resection of CRC at Saint-Antoine Hospital (Paris, France) from 18 to 1. Site of tumors was determined as 64 Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al
2 Table 1. Antibodies Used for Immunohistochemical Study Antigen Antibody Clone Dilution Time of Incubation Source hmlh1 hmsh2 hmsh6 hpms2 G FE :7 1: 1: 1:2 1h 3 min 3 min 3 min Pharmingen, San Diego, Calif Calbiochem, Cambridge, Mass Becton Dickinson, Franklin Lakes, NJ Oncogene Research Products, Cambridge, Mass rectum, left colon (distal to the splenic flexure), or right colon. Family cancer history was obtained from the clinical charts and was used to identify those families that met either the Amsterdam criteria or extended Bethesda criteria for HNPCC. 33,34 Histopathologic Review of Tumors For all tumors, all hematoxylin-phloxine-safranin stained slides were reviewed independently by 2 observers (V.R. and J.F.F.). The following variables were assessed: tumor grade (well, moderately, or poorly differentiated), extent of mucin production (mucinous cancers were those containing more than 5% of extracellular mucin), tumor growth pattern (expanding or infiltrating), 35 presence of a Crohn-like inflammatory infiltrate (defined as intense lymphoid reaction with numerous lymphoid aggregates with frequent germinal centers), 36 and intraepithelial lymphocytes (classified as conspicuous when more than 3 were present per 1 high-power fields).,37 The tumors were classified in the TNM, Dukes, Astler-Coller, and Jass 38 staging systems. A specific medullary type of cancer was recorded, characterized by uniform, poorly differentiated tumor cells arranged in solid sheets with a prominent intratumoral lymphocytic infiltrate. 3 Presence of residual adenomatous tissue around the cancer and of distant colonic polyps (hyperplastic, adenomatous, or serrated) was noted. Immunohistochemical Analysis One block of formalin-fixed, paraffin-embedded adenocarcinoma tissue was selected in each case. In all cases, this block comprised an area of normal colon mucosa adjacent to the tumor. Four-micrometer sections were affixed to Superfrost Plus slides (CML, Nemours, France) and dried overnight at 37 C. After dewaxing and rehydration in distilled water, endogenous peroxidase activity was quenched by incubating the slides in 3% hydrogen peroxide in methanol for (2 15 minutes). Sections were subject to heat antigen retrieval by autoclaving in citrate buffer (ph 6.) for 15 minutes at 75 W and 15 minutes at 15 W. Details of primary antibodies for MMR proteins, hmsh6, and hpms2 are summarized in Table 1. All incubations were performed at room temperature. The following methods were used: avidin-biotin complex method for hmlh1, indirect immunoperoxidase for hmsh2 and hmsh6, and supersensitive detection kit method (BioGenex, San Ramon, Calif) for hpms2. Immunohistochemical reactions were performed with the Optimax Plus system (BioGenex). Color was developed with aminoethyl-carbazole (Vector, Burlingame, Calif) as the chromogen. The sections were washed in running tap water and lightly counterstained in Mayer hematoxylin. The results were scored without knowledge of the MSI results. Loss of expression was recorded when nuclear staining was absent in all malignant cells, but preserved in normal epithelial and stromal cells. Two observers (V.R. and J.F.F.) assessed all cases independently. The few cases with discrepant scoring were reevaluated jointly on a second occasion, and agreement was reached in all cases. Microsatellite Instability Testing The same paraffin block was used for D extraction as for immunohistochemistry. D was extracted from both normal and malignant tissue embedded in paraffin. Selected areas of malignant tissue comprised more than 7% of malignant cells in all cases. Five to six 2- m sections were microdissected and placed into microcentrifuge tubes. D was extracted with the Qiamp tissue kit (Qiagen, Santa Clarita, Calif). The fluorescent multiplex microsatellite assay was used as previously described with a panel of the following 6 markers: D2S1, D5S346, D17S25, TGFbRII, BAT25, and BAT Tumors were considered MSI-H (high) if at least 2 markers showed instability and MSI-L (low) if only 1 marker was unstable. Statistical Analysis Qualitative data were compared with the 2 test using Yates correction when appropriate. Quantitative data were expressed as the mean SEM and compared by the Mann-Whitney test. A P value less than.5 was considered to indicate statistical significance. RESULTS Clinical and Pathologic Characteristics The patients ranged in age from 26 to years. One hundred twenty patients were women and 84 were men. Six patients fulfilled the Amsterdam criteria, and 3 met the extended Bethesda criteria for HNPCC syndrome. The cancers were located in the proximal colon (%), the distal colon (%), and the rectum (48%). The Astler-Coller stages were as follows: A, 11%; B1, 17%; B2, 28%; C1, 3%; C2, 3%; and D, 11%. Sixty-eight percent of tumors were well differentiated, 21% moderately differentiated, and 11% poorly differentiated. Fourteen percent of cases were mucinous, and 5% were of the medullary type. Frequency of MSI Thirty-one tumors (15%) were MSI-H, (11%) MSI-L, and 15 (74%) MSS. In MSI-H tumors, all 6 microsatellite markers showed instability in a majority of tumors. BAT26 was unstable in all 31 MSI-H tumors, and BAT25 was unstable in 25 of the 31 MSI-H tumors. Frequency of Loss of MMR Protein Thirty-five tumors (17%) lost the expression of 1 (13 cases) or 2 (22 cases) proteins. The following proteins were lost: hmlh1 alone (7 cases), hpms2 alone (4 cases), hmlh1 and hpms2 (15 cases) (Figure 1), hmsh6 alone (2 cases), and hmsh2 and hmsh6 (7 cases) (Figure 2). A comparison of microsatellite testing and immunohistochemistry results is presented in Table 2. All cases with loss of expression were MSI-H, except the 4 cases showing isolated loss of hpms2, which were MSS. There was no loss of expression of any protein in the MSI-L cases nor in the remaining 6 MSS cases. Therefore, when hmlh1, hmsh2, and hmsh6 expression was considered, there was a % sensitivity and specificity of immunohistochemistry for the MSI-H phenotype. The specificity, sensitivity, positive predictive value, and negative predictive value of immunohistochemistry for MSI are presented in Table 3, along with data from other published series. Relationship Between MMR Protein, HNPCC Clinical Criteria, and Mutation in MMR Genes Among the patients who fulfilled the Amsterdam or Bethesda clinical criteria for HNPCC syndrome, 4 had an Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al 65
3 Figure 1. Well-differentiated colorectal carcinoma with high microsatellite instability (A), showing loss of expression of hmlh1 (B) and hpms2 (C), and normal expression of hmsh2 (D) and hmsh6 (E) (A, hematoxylinphloxine-safranin, original magnification 2; B through E, immunoperoxidase, original magnification 4). hmlh1 germline mutation with loss of hmlh1 expression, 4 had an hmsh2 germline mutation with loss of expression of hmsh2 and hmsh6 proteins, and 1 had an hmsh6 germline mutation with loss of expression of hmsh6 protein (mutation data not shown). In one 36-year-old patient with loss of both hmsh2 and hmsh6 and in one 5-year-old patient with loss of hmsh6, no family history was obtained, and in one 33- year-old patient with loss of hmsh2 and hmsh6, there was a familial history of CRC insufficient to diagnose HNPCC. Relationship Between MMR Protein and Characteristics of the Tumors The relationship between loss of expression of MMR proteins and clinical and pathologic characteristics of the tumors is presented in Table 2. Tumors with a loss of hmlh1 expression occurred in older patients (P.1) and those with loss of expression of hmsh2 occurred in younger patients (P.1) than those with no loss of expression of either hmlh1 or hmsh2. Female sex was correlated with loss of hmlh1 (P.1). Proximal location of the tumor was associated with loss of hmlh1 (P.1) and hmsh2 (P.1). Poor differentiation was associated with loss of hmlh1 (P.1). Mucinous and medullary types were more frequent in tumors that were hmlh1 negative (P.1) and hmsh2 negative (P.1). Tumors showing loss of hmlh1 more often had expanding margins (P.2) and lower stages in the Astler-Coller system (P.1). There was no relationship between the expression of hmlh1 and hmsh2 and increased number of intratumorous lymphocytes, Crohnlike reaction, presence of adenomatous residue, T and N stage, or grade in Jass classification. COMMENT In this study, we compared tumor MSI testing by polymerase chain reaction versus tumor immunohistochemistry for assessing the competence of the MMR mechanism of CRCs. In our study, MSI-H tumors were seen in 15.2% of the cases. This rate is slightly higher than percentages previously reported in most studies.,17,1 This high rate could be partially explained by the presence of patients belonging to an HNPCC family in our population, as in most studies results were considered separately for HNPCC and sporadic MSI-positive CRCs. In our series, 11% of cases had an MSI-L phenotype. As in all reported series, MSI-L CRCs showed no loss of expression of MMR proteins. 7,16,17,32 Although some authors have proposed that the MSI-L phenotype reflects a distinctive pathway of development of CRC, 4 this theory is very much debated in the literature. 41 We do not furnish arguments in favor of this hypothesis, as MSI-L cases were similar to MSS cases 6 Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al
4 Figure 2. Well-differentiated colorectal carcinoma with high microsatellite instability (A), showing normal expression of hmlh1 (B) and hpms2 (C), and loss of expression of hmsh2 (D) and hmsh6 (E) (A, hematoxylinphloxine-safranin, original magnification 2; B through E, immunoperoxidase, original magnification 4). in regard to all clinicopathologic characteristics of the tumors. Our immunohistochemical analysis of MMR enzymes provided a highly specific and sensitive approach to the detection of MSI-H tumors. The performance of immunohistochemistry in comparison with molecular MSI testing is shown in Table 3, which presents the sensitivities, specificities, positive predictive values, and negative predictive values reported in previously published series of CRC and in the present series. As in most other series, we observed a predominance of loss of hmlh1 protein in MSI-H tumors, probably due to hypermethylation of the promoter of this gene in sporadic MSI-H cancers. 42 In most published studies, only 2 antibodies were used, directed against hmlh1 and hmsh2 proteins (Table 3). These 2 antibodies allowed a diagnosis of MSI with a high specificity (5% %) in almost all series, and usually with a high sensitivity, although in some studies this sensitivity was between 7% and 8%, with a relatively high number of false negatives.,1,21,26 When considering the results of 16 series representing 344 cases as a whole, the following performances of immunohistochemistry were obtained: sensitivity, 2.4%; specificity,.6%; positive predictive value, 8.5%; and negative predictive value, 7.8% (Table 3). Even if molecular MSI testing remains the current gold standard for assessing tumor D mismatch pair competency, all these studies confirm that hmlh1 and hmsh2 immunohistochemistry is a sensitive, rapid, and cost-effective method. Previous studies suggested that one explanation for false-negative cases obtained by immunohistochemistry might be the presence of mutations in still unidentified genes or in other MMR genes. 7,17 It seems therefore of interest to study the expression of other MMR proteins, such as hmsh6 and hpms2, that have been shown to be responsible for rare cases of HNPCC syndrome. We found cases that did not express hmsh6 protein, of which 7 cases also showed loss of hmsh2 expression and represented the entire group of tumors lacking hmsh2 expression. This association between hmsh2 and hmsh6 expression has already been reported by others. 11,32,43 We observed 2 cases with isolated loss of expression of hmsh6 protein, both of which were MSI-H. One patient had an HNPCC syndrome with a germline mutation of the hmsh6 gene, and the second patient was 5 years old. Although we did not have a family history in the latter case, this result might suggest that this patient also had an HNPCC syndrome, as hmsh6 is only rarely implicated in the development of MSI in sporadic CRCs. 32 In our series, these 2 cases lacking hmsh6 expression represented % of MSI-H tumors. Therefore, it seems interesting to study the expression of hmsh6 by immunohistochemistry when a clinical or morphological suspicion of MSI exists, especially when an HNPCC syndrome is sus- Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al 67
5 Table 2. Characteristics of Colorectal Adenocarcinomas and Results of Immunohistochemistry for Mismatch Repair Proteins in 24 Patients (All Numerical Results Are Expressed as Percentages Except the Mean Age in Years)* MSI status, % MSI-H MSI-L MSS Age, y (mean SD) Male sex, % Site, % Proximal Distal Rectum Differentiation, % Well-differentiated Moderately differentiated Poorly differentiated Histologic type, % Not otherwise specified Mucinous Medullary Expanding margins, % Increased intraepithelial lymphocytes, % Crohn-like reaction, % Adenomatous residue, % Astler-Coller stage, % A B1 B2 C1 C2 D pt stage, % T1 T2 T3 T4 pn stage, % N N1 N2 Jass stage, % I II III IV Lack of hmlh1 (n 22) Lack of hmsh2 (n 7) Lack of hmlh1 and/or hmsh2 and/or hmsh6 (n 31) Normal hmlh1, hmsh2 and hmsh6 (n 173) * MSI indicates microsatellite instability; MSI-H, at least 2 markers showed instability; MSI-L, only 1 marker showed instability; and MSS, microsatellite stable. Statistical comparison with tumors showing no loss of expression: P.1, P.1, and P pected, and when there is no loss of either hmlh1 or hmsh2 expression, although the MSI status of hmsh6- related tumors is still a matter of debate. 3,32,44 We also observed a close association between hmlh1 and hpms2 expression, as 15 of 22 cases with loss of hmlh1 also lacked hpms2, and 15 of 1 cases with loss of hpms2 also lacked hmlh1. This relationship between hmlh1 and hpms2 has been reported previously and is considered as secondary to the degradation of hpms2 in the absence of its binding partner, hmlh1. 11,32 We observed 4 cases with isolated loss of hpms2, but these 4 tumors were all MSS. It appears, therefore, that there is no need to include hpms2 in the panel of antibodies to be used when looking for MSI by immunohistochemistry. Although our unselected series mostly included sporadic CRCs, some cases developed in patients with an HNPCC syndrome. In our study, all cases identified by clinical criteria (Amsterdam or Bethesda) showed loss of expression of at least 1 MMR protein. However, it has been demonstrated recently that when a larger number of cases are studied, there is a significant proportion of cancer in HNPCC syndrome with germ-line mutation of hmlh1 or 68 Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al
6 Table 3. Reference, y Thibodeau et al, 16 1 Dietmaier et al, 5 17 Cawkwell et al, 17 1 Marcus et al, 18 1 Chaves et al, 1 2 Cawkwell et al, 2 2 Dieumegard et al, 21 2 Jass, 22 2 Iino et al, 24 2 Ward et al, 21 Young et al, Stone et al, Salahshor et al, Chiaravelli et al, Lindor et al, 22 Lanza et al, Plaschke et al, Present series Total of 16 series Results of Immunohistochemistry of Mismatch Repair (MMR) Proteins to Assess Microsatellite Instability in Previously Documented Series and in the Present Series* No. of Cases MMR Proteins Studied by Immunohistochemistry, hmsh6, hpms2, hmsh6, hpms2, hmsh6, hpms2... Sensitivity, % Specificity, % Positive Predictive Value, % Negative Predictive Value, % * indicates not available. Results calculated with hmlh1 and hmsh2,, and hmsh6, and, hmsh6, and hpms2 immunostainings. All series were included except Young et al 11 and Salahshor et al. 26 hmsh2 that remains positive on immunohistochemistry for these 2 proteins. 45 These apparent discrepancies between molecular and immunohistochemical results may be due to the synthesis of mutant proteins that are detected by immunohistochemistry, but that are not functionally active. If these results are confirmed in other series, they may indicate that immunohistochemistry is unlikely to be a primary test for detecting the presence of germline mutations in HNPCC cases. However, as immunohistochemistry is a simple and cheap technique, it can be used to indicate which gene has to be studied for mutation, in case the corresponding protein is not expressed in the tumor. 46 In sporadic cancers, false-negative immunohistochemical results are unlikely to occur, because in most MSI-H tumors the promoter for the MMR gene is turned off by hypermethylation, and then no protein is produced. Immunohistochemistry could therefore be a useful screening method to detect MSI-H cases, which may need different chemotherapy. In our series, we observed the same clinical and morphologic characteristics of MSI-H CRCs that have been described previously: frequent loss of hmlh1 expression in elderly women, excess of mucinous and medullary types, poorly differentiated cancers, and circumscribed borders. 6,,11 On the contrary, none of these features was related to the MSI-L phenotype. However, although some features are relatively specific for the MSI-H phenotype, they cannot be used as the only detection test, owing to their low sensitivity. 6,1 Moreover, we did not confirm the relationship between the MSI-H phenotype and other features previously described in the literature, such as a Crohn-like lymphoid response and an increased number of intraepithelial lymphocytes. 6, 11,37 These discrepancies may be at least partially due to the relatively subjective diagnosis of these features, with criteria variable in different studies. For the intraepithelial lymphocyte count, it may also be explained by the count that we performed on hematoxylin-eosin stained sections, contrary to most studies with a count made by immunohistochemistry for T lymphocytes. 1,37 It seems therefore necessary to include an immunohistochemical study of MMR proteins when the MSI phenotype has to be determined in a large series of patients. In conclusion, our findings confirm that examination of MMR protein expression by immunohistochemistry is a simple method for diagnosing CRC with MSI. Our data suggest that the study of hmsh6 may be useful, in addition to hmlh1 and hmsh2. Moreover, immunohistochemistry could represent a screening method to direct the research of mutation of MMR genes observed in HNPCC syndrome, and to detect MSI-H sporadic CRCs that may need different chemotherapy. The authors acknowledge the Fonds de Recherche de la Société Nationale Française de Gastroentérologie (Tours, France), the Fonds de Recherche de la Société Française de Pathologie (Paris, France), and the Association Charles Debray (Chevigny Saint- Sauveur, France). Dr Rigau was supported by the Association pour la Recherche sur le Cancer (Villejuif, France). References 1. Lynch HT, De La Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1;36: Rüschoff J, Bocker T, Schlegel J, Stumm G, Hofstaedter F. Microsatellite instability: new aspects in the carcinogenesis of colorectal carcinoma. Virchows Arch. 15;426: Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 13;363: Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al 6
7 4. Fujiwara T, Stolker JM, Watanabe T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol. 18;153: Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Rüschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 17;57: Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with D replication errors. Gut. 18;42: Nicholl ID, Dunlop MG. Molecular markers of prognosis in colorectal cancer. J Natl Cancer Inst. 1;1: Purdie CA, Piris J. Histopathological grade, mucinous differentiation and D ploidy in relation to prognosis in colorectal carcinoma. Histopathology. 2;36: Ward R, Meagher A, Tomlinson I, et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 21;48: Alexander J, Watanabe T, Wu T-T, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 21;158: Young J, Simms LA, Biden KG, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 21;15: Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2;342: Wright CM, Dent OF, Barker M, et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg. 2;87: Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2;355: Boland CR, Thibodeau SN, Hamilton SR, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 18;58: Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hmsh2 and hmlh1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1;56: Cawkwell L, Gray S, Murgatroyd H, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut. 1;45: Marcus VA, Madlensky L, Gryfe R, et al. Immunohistochemistry for hmlh1 and hmsh2: a practical test for D mismatch repair- deficient tumors. Am J Surg Pathol. 1;: Chaves P, Cruz C, Lage P, et al. Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype. J Pathol. 2;11: Cawkwell L, Sutherland F, Murgatroyd H, et al. Defective hmsh2/hmlh1 protein expression is seen infrequently in ulcerative colitis associated colorectal cancers. Gut. 2;46: Dieumegard B, Grandjouan S, Sabourin JC, et al. Extensive molecular screening for hereditary colorectal cancer. Br J Cancer. 2;82: Jass JR. hmlh1 and hmsh2 immunostaining in colorectal cancer. Gut. 2;47: Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski J. Value of pedigree, clinical data, immunohistochemistry and microsatellite instability analyses in reducing the cost of determining hmlh1 and hms2 gene mutations in patients with colorectal cancer. Eur J Cancer. 2;36: Iino H, Simms L, Young J, et al. D microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut. 2;47: Stone JG, Robertson D, Houlston RS. Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer. J Clin Pathol. 21;54: Salahshor S, Koelble K, Rubio C, Lindblom A. Microsatellite instability and hmlh1 and hmsh2 expression analysis in familial and sporadic colorectal cancer. Lab Invest. 21;81: Chiaravalli AM, Furlan D, Facco C, et al. Immunohistochemical pattern of hmsh2/hmlh1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch. 21;438: Perrin J, Gouvernet J, Parriaux D, et al. MSH2 and MLH1 immunodetection and the prognosis of colon cancer. Int J Oncol. 21;1: Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 22;2: De La Chapelle A. Microsatellite instability phenotype of tumors: genotyping or immunohistochemistry? The jury is still out. J Clin Oncol. 22;2: Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 22;15: Plaschke J, Kruger S, Pistorius S, Theissig F, Saeger HD, Schackert HK. Involvement of hmsh6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int J Cancer. 22;7: Vasen HFA, Watson P, Meklin J-P, Lynch HT, and the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1;116: Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 17;8: Jass JR, Ajioka Y, Allen JP, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology. 1;28: Graham DM, Appelman HD. Crohn s-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol. 1;3: Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut. 21;48: Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 187;1: Hamilton SR, Aaltonen LA. Pathology and genetics: tumours of the digestive system. In: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2: Iino H, Jass JR, Simms LA, et al. D microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol. 1;52: Tomlinson I, Halford S, Aaltonen L, Hawkins N, Ward R. Does MSI-low exist? J Pathol. 22;17: Kane MF, Loda M, Gaida GM, et al. Methylation of the hmlh1 promoter correlates with lack of expression of hmlh1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 17;57: Schweizer P, Moisio AL, Kuismanen SA, et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res. 21;61: Parc YR, Halling KC, Wang L, et al. hmsh6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res. 2;6: Wahlberg SS, Schmeits J, Thomas G, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 22;62: Paraf F, Gilquin M, Longy M, et al. MLH1 and MSH2 protein immunohistochemistry is useful for detection of hereditary non-polyposis colorectal cancer in young patients. Histopathology. 21;3: Arch Pathol Lab Med Vol 127, June Microsatellite Instability in Colorectal Carcinoma Rigau et al
Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability
The Korean Journal of Pathology 29; 43: 428-34 DOI: 1.4132/KoreanJPathol.29.43.5.428 Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability Sang Kyum Kim Junjeong
More informationHyperplastic polyps in hereditary nonpolyposis colorectal cancer
4 Hyperplastic polyps in hereditary nonpolyposis colorectal cancer F E M Rijcken 1, T van der Sluis 2, H Hollema 2, J H Kleibeuker 1 Department of Gastroenterology 1 and Pathology 2, University Medical
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationClinicopathologic Factors Identify Sporadic Mismatch Repair Defective Colon Cancers
Anatomic Pathology / MORPHOLOGY IN MMR-DEFECTIVE COLON CANCER Clinicopathologic Factors Identify Sporadic Mismatch Repair Defective Colon Cancers Britta Halvarsson, MD, PhD, 1 Harald Anderson, PhD, 2 Katarina
More informationDefective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $30.00 www.modernpathology.org Defective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas Joseph Misdraji
More informationA Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationColorectal carcinoma (CRC) was traditionally thought of
Testing for Defective DNA Mismatch Repair in Colorectal Carcinoma A Practical Guide Lawrence J. Burgart, MD Context. Significant bench and clinical data have been generated during the last decade regarding
More informationChoice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair
Gut 1999;45:409 415 409 Molecular Oncology, Algernon Firth Institute of Pathology, School of Medicine, University of Leeds, Leeds, UK L Cawkwell H Murgatroyd F Sutherland L Haine S O Loughlin N Mapstone
More informationCase Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr
Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationThe Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto
Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationCME/SAM. Poorly Differentiated Colorectal Cancers. Correlation of Microsatellite Instability With Clinicopathologic Features and Survival
Poorly Differentiated Colorectal Cancers Correlation of Microsatellite Instability With Clinicopathologic Features and Survival Haitao Xiao, MD, 1,2 Yong Sik Yoon, MD, 1,3 Seung-Mo Hong, MD, 4 Seon Ae
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationMedicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY Observational Study: Familial Relevance and Oncological Significance of Revised Bethesda Guidelines in Colorectal Patients That Have Undergone Curative Resection Won Beom Jung,
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationMismatch repair protein expression in colorectal cancer
Original Article Mismatch repair protein expression in colorectal cancer Elrasheid A. H. Kheirelseid 1, Nicola Miller 1, Kah Hoong Chang 1, Catherine Curran 1, Emer Hennessey 1, Margaret Sheehan 2, Michael
More informationASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY OBJECTIVES
ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY Authors: Duilio Della Libera, Alessandra D Urso, Federica Modesti, Georgeta Florea, Marta Gobbato Hospital:
More informationKeywords: microsatellite instability; multiple primary cancer; hereditary non-polyposis colorectal cancer
790 Gut 2000;46:790 794 First Department of Internal Medicine, Sapporo Medical University, Sapporo, K Yamashita Y Arimura S Kurokawa F Itoh T Endo K Imai First Department of Surgery, Sapporo Medical University,
More informationT he lifetime risk of developing colorectal cancer is 5%, with. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer CANCER
228 CANCER Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer G Lindgren, A Liljegren, E Jaramillo, C Rubio, A Lindblom... See end of article for authors affiliations... Correspondence
More informationMismatch repair protein expression in patients with stage II and III sporadic colorectal cancer
ONCOLOGY LETTERS 15: 8053-8061, 2018 Mismatch repair protein expression in patients with stage II and III sporadic colorectal cancer LIHUA ZHAO Department of Pathology, Beijing Civil Aviation Hospital,
More informationHyperplastische Polyps Innocent bystanders?
Hyperplastische Polyps Innocent bystanders?? K. Geboes P th l i h O tl dk d Pathologische Ontleedkunde, KULeuven Content Historical Classification Relation Hyperplastic polyps carcinoma The concept cept
More informationCAP Laboratory Improvement Programs. Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys
CAP Laboratory Improvement Programs Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys Proficiency Survey Results From 2005 to 2012 Theresa A. Boyle,
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationHereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics
From clinic to genetics Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Autosomal dominant Question 2) Incidence of
More informationContent. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
More informationFamily history and molecular features of children, adolescents, and young adults with colorectal carcinoma
1146 COLON CANCER Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma C Durno, M Aronson, B Bapat, Z Cohen, S Gallinger... See end of article for
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationFAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry
FAMILIAL COLORECTAL CANCER Lyn Schofield Manager Familial Cancer Registry Cancer in WA 2004 4000 3500 ASPR, rate per 100,000 3000 2500 2000 1500 1000 Male incidence Female incidence Male mortality Female
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationVENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue VENTANA anti-mlh1 (M1) Mouse Monoclonal Primary Antibody VENTANA anti-pms2 (A16-4) Mouse Monoclonal Primary Antibody VENTANA
More informationDall istologia alla caratterizzazione biomolecolare
Il carcinoma ovarico: approccio multidisciplinare e prospettive terapeutiche Dall istologia alla caratterizzazione biomolecolare Anna Pesci Ospedale SC Don Calabria, Negrar anna.pesci@sacrocuore.it Ovarian
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationThe Frequency of Muir-Torre Syndrome Among Lynch Syndrome Families
BRIEF COMMUNICATION The Frequency of Muir-Torre Syndrome Among Lynch Syndrome Families Christopher D. South, Heather Hampel, Ilene Comeras, Judith A. Westman, Wendy L. Frankel, Albert de la Chapelle Lynch
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationArthur Purdy Stout Society of Surgical Pathologists Companion Meeting. Microsatellite Instability and Serrated Adenomas in Common Practice
Arthur Purdy Stout Society of Surgical Pathologists Companion Meeting Microsatellite Instability and Serrated Adenomas in Common Practice United States and Canadian Academy of Pathology Annual Meeting
More informationClinical significance of mismatch repair genes immunohistochemical expression of complex endometrial hyperplasia
Original Article Obstet Gynecol Sci 2015;58(2):106-111 http://dx.doi.org/10.5468/ogs.2015.58.2.106 pissn 2287-8572 eissn 2287-8580 Clinical significance of mismatch repair genes immunohistochemical expression
More informationMSI test to distinguish between HNPCC and other predisposing syndromes of value in tailored surveillance 1
Disease Markers 20 (2004) 259 267 259 IOS Press MSI test to distinguish between HNPCC and other predisposing syndromes of value in tailored surveillance 1 Annelie Liljegren a,c, Louise Olsson b and Annika
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationP rognosis in colorectal cancer has been associated with two
69 ORIGINAL ARTICLE APC mutation and tumour budding in colorectal cancer J R Jass, M Barker, L Fraser, M D Walsh, VLJWhitehall, B Gabrielli, J Young, B A Leggett... See end of article for authors affiliations...
More informationReview Article Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer
SAGE-Hindawi Access to Research Molecular Biology International Volume 2011, Article ID 256063, 6 pages doi:10.4061/2011/256063 Review Article Relationship between DNA Mismatch Repair Deficiency and Kenta
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationAssessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.
Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers. Soheila Hamidpour MD, Madhusudhana S MD. MMR deficient colorectal tumors can be present
More informationMicrosatellite instability in colorectal-cancer patients with suspected genetic predisposition.
Chapter 3 Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, Sala P, Eboli M, Andreola
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationFROM EDUCATION TO TUMOUR CHARACTERISTICS IN COLORECTAL CANCER: AN ANALYSIS OF THE PATHWAYS
FROM EDUCATION TO TUMOUR CHARACTERISTICS IN COLORECTAL CANCER: AN ANALYSIS OF THE PATHWAYS By Parisa Airia A thesis submitted in conformity with the requirements for the degree of PhD Dalla Lana School
More informationThe Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer
Gut and Liver, Vol. 9, No. 2, March 215, pp. 22-27 ORiginal Article The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer Ki Joo Kang*, Byung-Hoon Min, Kyung Ju Ryu, Kyoung-Mee
More informationP rimary adenocarcinomas of the small intestine are rare,
898 ORIGINAL ARTICLE Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray study M Svrcek, F Jourdan, N Sebbagh, A Couvelard, D Chatelain, N Mourra, S Olschwang, D
More informationSpecial Section Hereditary Colorectal Cancer. What s New in Hereditary Colorectal Cancer? Jeremy R. Jass, MD, DSc, FRCPath, FRCPA
Special Section Hereditary Colorectal Cancer What s New in Hereditary Colorectal Cancer? Precancerous polyposes other than classic familial adenomatous polyposis and the condition hereditary nonpolyposis
More information2004 Landes Bioscience. Not for distribution.
[Cancer Biology & Therapy 3:1, 73-78, January 2004]; 2004 Landes Bioscience Research Paper Evaluation of Microsatellite Instability, hmlh1 Expression and hmlh1 Promoter Hypermethylation in Defining the
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationTumors associated with Hereditary Nonpolyposis Colorectal Cancer: Defective Mismatch Repair and Familial Risk of Cancer
Tumors associated with Hereditary Nonpolyposis Colorectal Cancer: Defective Mismatch Repair and Familial Risk of Cancer Ericson Lindquist, Kajsa Published: 2005-01-01 Link to publication Citation for published
More informationMorphology of sporadic colorectal cancer with DNA replication errors
Gut 1998;42:673 679 673 Department of Pathology JRJass Department of Surgery, University of Queensland C Wynter S P Pillay Glaxo Conjoint Gastroenterology Laboratory L A Simms G Radford-Smith J Young B
More informationThe pathological phenotype of colon cancer with microsatellite instability
Dan Med J 63/2 February 2016 danish medical JOURNAL 1 The pathological phenotype of colon cancer with microsatellite instability Helene Schou Andersen 1, 2, Claus Anders Bertelsen 1, Rikke Henriksen 1,
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationReplication error phenotype, clinicopathological variables, and patient outcome in Dukes B stage II (T3,N0,M0) colorectal cancer
200 Department of Pathology, Royal College of Surgeons in Ireland, Dublin, Republic of Ireland B Curran EWKay M Leader Department of Biochemistry K Lenehan O Tighe M A Bennett D T Croke Gastroenterology
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationcase report Reprinted from August 2013
Reprinted from August 2013 A 48-year-old woman with endometrial cancer Importance of screening for Lynch syndrome in patients with EC CAP TODAY and the Association for Molecular Pathology have teamed up
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationReduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer
Imaging, Diagnosis, Prognosis Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer Alberto Malesci, 1,6 Luigi Laghi, 1,5 Paolo Bianchi, 5 Gabriele Delconte, 1 Ann
More informationLoss of Mismatch Repair Protein Expression in Epithelial Ovarian Carcinoma: A Histomorphologic Guide to Targeted Screening
Loss of Mismatch Repair Protein Expression in Epithelial Ovarian Carcinoma: A Histomorphologic Guide to Targeted Screening Eman Abdulfatah a, Sharif Sakr b, Sumi Thomas a, Sudeshna Bandyopadhyay a, Kavita
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationThe College of American Pathologists (CAP) offers these
CAP Laboratory Improvement Programs Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium Teri A. Longacre, MD; Russell Broaddus, MD, PhD; Linus
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationMolecular aspects of HNPCC and identification of mutation carriers Niessen, Renee
University of Groningen Molecular aspects of HNPCC and identification of mutation carriers Niessen, Renee IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationChallenges and Pitfalls in HNPCC Screening by Microsatellite Analysis and Immunohistochemistry
Journal of Molecular Diagnostics, Vol. 6, No. 4, November 2004 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology Challenges and Pitfalls in HNPCC Screening
More informationp53 expression in invasive pancreatic adenocarcinoma and precursor lesions
Malaysian J Pathol 2011; 33(2) : 89 94 ORIGINAL ARTICLE p53 expression in invasive pancreatic adenocarcinoma and precursor lesions NORFADZILAH MY MBBCH,* Jayalakshmi PAILOOR MPath, FRCPath,* RETNESWARI
More informationHereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD
Hereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD Living Beyond Cancer A-Z January 12,2019 Hereditary CRC Syndromes Objectives are to discuss the : Most common Hereditary CRC syndromes
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationMr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer
Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth
More informationNew Strategy For Treatment Of Hereditary Colorectal Cancer By Shozo Baba
New Strategy For Treatment Of Hereditary Colorectal Cancer By Shozo Baba If you are looking for a book by Shozo Baba New Strategy for Treatment of Hereditary Colorectal Cancer in pdf form, then you have
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2018 Origination: 1/2004 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationPage 1 of 8 TABLE OF CONTENTS
Page 1 of 8 TABLE OF CONTENTS Patient Evaluation and Recommendation..Page 2 Testing and Follow-up..Page 3 Genetic Counseling Referral Criteria.....Page 4-5 Patient Education..Page 6 Suggested Readings...Page
More informationSynchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum
Tsumura T, et al 1 Synchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum T. Tsumura a T. Hiyama d S. Tanaka b M. Yoshihara d K. Arihiro c K. Chayama a Departments
More informationA missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-italy
DOI 10.1007/s10689-006-9110-z ORIGINAL PAPER A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-italy Francesca Bianchi Æ Eva Galizia Æ Emilio Porfiri Æ Laura Belvederesi
More information